<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01364415</url>
  </required_header>
  <id_info>
    <org_study_id>CSOM230D2101</org_study_id>
    <nct_id>NCT01364415</nct_id>
  </id_info>
  <brief_title>Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)</brief_title>
  <official_title>A Phase I, Multi-center, Open-label, Dose Escalation Study of Pasireotide (SOM230) LAR in Patients With Advanced Neuroendocrine Tumors (NETs)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study designed to determine the Maximum Tolerated Dose (MTD) for patients with advanced
      Neuroendocrine Tumors (NETs) and to characterize the safety, tolerability, Pharmacokinetics
      and preliminary efficacy of pasireotide LAR administered i.m. once every 28 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the MTD/RP2D of pasireotide LAR when administered i.m. q28 days to patients with advanced NETs</measure>
    <time_frame>Sequentiona 56 day cohorts until the MTD is determined</time_frame>
    <description>Frequency of dose-limiting toxicities (DLTs) at each dose level associated with q28 days administration of pasireotide LAR during the first 2 treatment cycles.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>assess the safety and tolerability of pasireotide LAR</measure>
    <time_frame>minimum of twelve 28 day cycles to approximately eighteen 28 day cycles</time_frame>
    <description>Incidence of adverse drug events, overall and by severity and incidence of serious adverse events and laboratory abnormalities. Also, changes in laboratory assessments, electrocardiograms, Holter monitor, imaging for gallstones, and assessment of physical examinations such as vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assess the pharmacokinetics (PK) of pasireotide LAR</measure>
    <time_frame>minimum of twelve 28 day cycles to approximately eighteen 28 day cycles</time_frame>
    <description>Pasireotide Cmax and Ctrough</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assess the pharmacodynamics (PD) of pasireotide LAR</measure>
    <time_frame>minimum of twelve 28 day cycles to approximately eighteen 28 day cycles</time_frame>
    <description>Changes from baseline values in IGF-1, chromogranin A and neuron-specific enolase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assess the preliminary efficacy (anti-tumor activity) of pasireotide LAR.</measure>
    <time_frame>minimum of twelve 28 day cycles to approximately eighteen 28 day cycles</time_frame>
    <description>Disease control rate (CR+PR+SD as assessed by RECIST 1.0). Also measure progression free survival (PFS).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <arm_group>
    <arm_group_label>Pasireotide LAR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pasireotide LAR</intervention_name>
    <arm_group_label>Pasireotide LAR</arm_group_label>
    <other_name>SOM230</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥18 yrs old, histologically confirmed advanced well or moderately differentiated
             neuroendocrine tumor/carcinoma

          -  unresectable metastatic NET tumor with measurable disease

          -  life expectancy ≥ 12 weeks

        Exclusion Criteria:

          -  Patients with CNS metastases who are neurologically unstable or requiring increasing
             doses of steroids to control their CNS disease

          -  patients with known hypersensitivity to somatostatin analogs

          -  patients with symptomatic cholelithiasis in the past 2 months

          -  patients with history of another known primary malignancy with exception of
             non-melanoma skin cancer or carcinoma in situ of uterine cervix

          -  patients with known history of hepatitis C or chronic active hepatitis B

          -  patients with diagnosis of HIV.

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center Cedars Sinai 4</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute SC-1</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute SC-6</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas/MD Anderson Cancer Center UT MD Anderson Cancer Ctr</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2011</study_first_submitted>
  <study_first_submitted_qc>June 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2011</study_first_posted>
  <last_update_submitted>June 27, 2016</last_update_submitted>
  <last_update_submitted_qc>June 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MTD</keyword>
  <keyword>pasireotide</keyword>
  <keyword>LAR</keyword>
  <keyword>NETs</keyword>
  <keyword>advanced neuroendocrine tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pasireotide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

